The final, formatted version of the article will be published soon. AML patients with FLT3-ITD experience shorter disease-free survival and high relapse rates even with FLT3inhibitor therapy. One of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback